About
Provided by Goodwin Procter LLP
Our Technology, Life Sciences, and Emerging Companies Practice is rooted in partnering with, and supporting, companies on their journey throughout the corporate lifecycle, no matter the stage or growth path they choose. Goodwin is highly regarded in these verticals as a result of our tenured experience, vast platform, and deep expertise guiding emerging technology and life sciences companies throughout their maturation and ultimately through exit and beyond. By partnering with us for their most meaningful transactions, our clients are able to further maximize their position within the marketplace and fuel their growth. We work with our clients across the full suite of company and investor lifecycle needs, including through:
· Company Formation
· Financings (early- through late-stage)
· Capital Markets Transactions, such as IPOs, SPACs, or Direct Listings
· M+A Transactions (Buy- and Sell-Side, #1 in Global M&A by deal count per Refinitiv in 2022)
· Regulatory + FDA Matters
· Tax
· Technology Transaction, including IP Transactions, such as Licensing, Collaborations, and Joint Ventures, in addition to Patent and Trademark Prosecution, Portfolio Management and Diligence
· Offshore + Cross-Border Transactions
· Tender Offers
· Debt Transactions
· Data Privacy + Cybersecurity
· Executive Compensation
